1-9 of 9
Shinya Kimura
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: HLA Polymorphisms Are Associated With Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Free
Hiroshi Ureshino, Takero Shindo, Hidenori Tanaka, Hiroh Saji, Shinya Kimura
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (5): 855.
https://doi.org/10.1158/1535-7163.MCT-22-0146
Published: 04 May 2022
View articletitled, Correction: HLA Polymorphisms Are Associated With Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Open the PDF for Correction: HLA Polymorphisms Are Associated With Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in another window
Journal Articles

Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects

Open Access
Hiroshi Ureshino, Yuki Kurahashi, Tatsuro Watanabe, Satoshi Yamashita, Kazuharu Kamachi, Yuta Yamamoto, Yuki Fukuda-Kurahashi, Nao Yoshida-Sakai, Naoko Hattori, Yoshihiro Hayashi, Atsushi Kawaguchi, Kaoru Tohyama, Seiji Okada, Hironori Harada, Toshikazu Ushijima, Shinya Kimura
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (8): 1412–1421.
https://doi.org/10.1158/1535-7163.MCT-20-1125
Published: 01 August 2021
View articletitled, Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects
Open the PDF for Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects in another window
Journal Articles

HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Available to Purchase
Hiroshi Ureshino, Takero Shindo, Hidenori Tanaka, Hiroh Saji, Shinya Kimura
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (1): 142–149.
https://doi.org/10.1158/1535-7163.MCT-20-0336
Published: 01 January 2021
View articletitled, HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Open the PDF for HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome–Positive Lymphoid Leukemia

Free
Atsushi Nemoto, Satoshi Saida, Itaru Kato, Jiro Kikuchi, Yusuke Furukawa, Yasuhiro Maeda, Koshi Akahane, Hiroko Honna-Oshiro, Kumiko Goi, Keiko Kagami, Shinya Kimura, Yuko Sato, Seiichi Okabe, Akira Niwa, Kenichiro Watanabe, Tatsutoshi Nakahata, Toshio Heike, Kanji Sugita, Takeshi Inukai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (1): 94–105.
https://doi.org/10.1158/1535-7163.MCT-14-1065
Published: 07 January 2016
View articletitled, Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome–Positive Lymphoid Leukemia
Open the PDF for Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome–Positive Lymphoid Leukemia in another window
Includes: Supplementary data
Journal Articles

Abstract A130: Targeting BMI-1 by the novel BMI-1 inhibitor PTC596 in acute leukemia

Free
Yuki Nishida, Aya Maeda, Liangxian Cao, Melissa Dumble, Shinya Kimura, Thomas W. Davis, Kensuke Kojima
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A130.
https://doi.org/10.1158/1535-7163.TARG-15-A130
Published: 01 December 2015
View articletitled, Abstract A130: Targeting BMI-1 by the novel BMI-1 inhibitor PTC596 in acute leukemia
Journal Articles

Abstract C157: Identification of a novel DNA topoisomerase II inhibitor by proteomic profiling

Free
Makoto Kawatani, Hiroshi Takayama, Makoto Muroi, Shinya Kimura, Taira Maekawa, Hiroyuki Osada
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C157.
https://doi.org/10.1158/1535-7163.TARG-09-C157
Published: 10 December 2009
View articletitled, Abstract C157: Identification of a novel DNA topoisomerase II inhibitor by proteomic profiling
Journal Articles

Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer

Free
Eri Kawata, Eishi Ashihara, Shinya Kimura, Kazumasa Takenaka, Kiyoshi Sato, Ruriko Tanaka, Asumi Yokota, Yuri Kamitsuji, Miki Takeuchi, Junya Kuroda, Fumihiro Tanaka, Toshikazu Yoshikawa, Taira Maekawa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (9): 2904–2912.
https://doi.org/10.1158/1535-7163.MCT-08-0473
Published: 11 September 2008
View articletitled, Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer
Open the PDF for Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer in another window
Includes: Supplementary data
Journal Articles

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells

Free
Linhua Jin, Yoko Tabe, Sergej Konoplev, Yuanyuan Xu, Clinton E. Leysath, Hongbo Lu, Shinya Kimura, Akimichi Ohsaka, Mary-Beth Rios, Leslie Calvert, Hagop Kantarjian, Michael Andreeff, Marina Konopleva
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (1): 48–58.
https://doi.org/10.1158/1535-7163.MCT-07-0042
Published: 17 January 2008
View articletitled, CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
Open the PDF for CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells in another window
Journal Articles

Antitumor effect of IKKβ inhibitor IMD-0354 on bortezomib-resistant multiple myeloma cells

Free
Akiko Taniyama, Yasuhito Terui, Yuji Mishima, Ryoko Kuniyoshi, Kiyotsugu Kojima, Susumu Muto, Teruko Itai, Shinya Kimura, Kiyohiko Hatake
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A174.
Published: 01 November 2007
View articletitled, Antitumor effect of IKKβ inhibitor IMD-0354 on bortezomib-resistant multiple myeloma cells